Named Bioactive Compounds · Compound
Solasodine
Moderate Evidencecompound2 PubMed Studies
Hermetica Superfood Encyclopedia
Solasodine is a steroidal alkaloid glycoside found in Solanum plants that demonstrates anticancer properties through multiple cellular pathways. This bioactive compound works by inhibiting cancer cell proliferation, inducing apoptosis, and potentially reducing chemotherapy resistance in laboratory studies.
Solasodine is a steroidal alkaloid naturally found in plants of the Solanaceae (nightshade) family, particularly various Solanum species including Solanum sisymbriifolium and Solanum nigrum. This nitrogen-containing organic compound with a steroid-like structure is extracted from these plants for research purposes.
Current research on solasodine consists entirely of in vitro cell culture studies and animal model experiments, with no human clinical trials identified. Studies have demonstrated anti-cancer effects in colorectal cancer cell lines (IC₅₀ values 39-50 μmol/L), gastric cancer cells through Hedgehog signaling inhibition, and reduced tumor growth in pancreatic cancer mouse models at 10-40 mg/kg doses.
Animal studies have used: 10-40 mg/kg body weight (peritoneal injection for cancer models); 1-10 mg/kg body weight (oral administration for asthma models). In vitro cancer studies used 20-80 μmol/L concentrations. No human dosage recommendations exist. Consult a healthcare provider before starting any new supplement.
Solasodine is not a nutrient or food but a steroidal alkaloid aglycone (C27H43NO2, MW ~413.64 g/mol) found in various Solanum species. It is the aglycone (non-sugar) portion of solasonine and solamargine glycoalkaloids. Key chemical and bioactive profile: • Classified as a spirosolane-type steroidal alkaloid with a nitrogen-containing heterocyclic ring system • Naturally occurring concentrations vary by plant source: Solanum khasianum (unripe berries: ~1.5–4% dry weight), Solanum nigrum (fruits/leaves: ~0.1–0.8% dry weight), Solanum incanum (~1–3% dry weight), Solanum laciniatum (~0.5–2.5% dry weight) • Not a source of macronutrients (protein, carbohydrates, fat), vitamins, or minerals — it is a single bioactive alkaloid compound • Structurally related to cholesterol and serves as a precursor for the semi-synthesis of steroidal hormones (progesterone, cortisone, and other corticosteroids) in pharmaceutical manufacturing • Lipophilic in nature with moderate oral bioavailability; absorption is enhanced when present in glycosylated forms (solasonine, solamargine) which are cleaved by gut enzymes to release solasodine • Contains no fiber, no significant caloric value, and no vitamin/mineral content • Bioavailability notes: Oral bioavailability in animal models is estimated to be low-to-moderate due to hepatic first-pass metabolism; glycoalkaloid forms (solasonine, solamargine) show improved intestinal absorption compared to free solasodine; the compound undergoes phase I and phase II hepatic metabolism; plasma half-life in rodent models is relatively short (~2–4 hours) • Key functional groups contributing to bioactivity include the 3β-hydroxyl group, the spiroaminoketal nitrogen, and the overall rigid steroidal backbone • Solasodine itself has no recognized nutritional value and is studied exclusively as a pharmacologically active phytochemical, not as a dietary supplement or nutrient
Solasodine exerts its anticancer effects by disrupting mitochondrial membrane potential and triggering intrinsic apoptotic pathways through cytochrome c release. The compound inhibits PI3K/AKT signaling pathways while activating p53-mediated cell cycle arrest. Additionally, solasodine appears to modulate multidrug resistance proteins, potentially reversing chemotherapy resistance in cancer cells.
Current evidence for solasodine comes exclusively from in vitro cell culture studies and animal xenograft models, with no published human clinical trials. Laboratory studies show significant inhibition of colorectal, gastric, and pancreatic cancer cell lines at concentrations ranging from 10-50 μM. Animal studies demonstrate tumor growth reduction of 40-60% in xenograft models when combined with conventional chemotherapy. The lack of human studies significantly limits the clinical applicability of these promising preclinical findings.
Safety data for solasodine in humans is extremely limited due to the absence of clinical trials. As a steroidal alkaloid, it may potentially interact with medications metabolized by cytochrome P450 enzymes and could affect steroid hormone pathways. Theoretical concerns include possible effects on blood glucose levels and potential hepatotoxicity at high doses. Pregnant and breastfeeding women should avoid solasodine-containing supplements due to insufficient safety data and potential teratogenic effects of steroidal alkaloids.
